K Dujardin1, N Auzou2, E Lhommée3, V Czernecki4, B Dubois5, A Fradet6, D Maltete7, M Meyer8, F Pineau9, E Schmitt10, F Sellal11, F Tison12, T Vidal13, J-P Azulay14, M-L Welter15, J-C Corvol16, F Durif17, O Rascol18. 1. Université de Lille, Inserm U1171, Degenerative & Vascular Cognitive Disorders, 59000 Lille, France; CHU de Lille, Neurology and Movement Disorders, 59000 Lille, France. Electronic address: kathy.dujardin@univ-lille2.fr. 2. Institute of Neurodegenerative Disorders, CHU de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Psychology Laboratory, EA4139, 33000 Bordeaux, France. 3. CHU de Grenoble Alpes, Inserm U1216, 38000 Grenoble, France; Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), 38000 Grenoble, France. 4. CRICM UMRS 975, Neurology Department, AP-HP, Salpetrière Hospital, 75013 Paris, France. 5. Université Pierre-et-Marie-Curie, Paris VI, ICM, Inserm UMR_S975, Dementia Research Center (IM2A), Salpêtrière Hospital, 75013 Paris, France. 6. CHU de Poitiers, Neurology & Neuropsychology, Expert Referent Center of Parkinson Disease, CMRR, 86000 Poitiers, France. 7. Department of Neurology, Rouen University Hospital, 76031 Rouen, France; Inserm U1073, Rouen Faculty of Medicine, 76031 Rouen, France. 8. CHU de Nancy, Department of Neurology, 54000 Nancy, France. 9. Département de Neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France. 10. Université Pierre-et-Marie-Curie, Paris VI, ICM, Inserm UMR_S975, Dementia Research Center (IM2A), Salpêtrière Hospital, 75013 Paris, France; CHU de Poitiers, Neurology & Neuropsychology, Expert Referent Center of Parkinson Disease, CMRR, 86000 Poitiers, France. 11. Département de Neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France; Inserm U1118, Université de Strasbourg, 67085 Strasbourg, France. 12. Institute of Neurodegenerative Disorders, CHU de Bordeaux, 33000 Bordeaux, France. 13. CHU de Clermont-Ferrand, Movement Disorders Centre, 63000 Clermont-Ferrand, France; CHU de Clermont-Ferrand, Resource and Research Memory Centre, 63000 Clermont-Ferrand, France. 14. Neurology and Movement Disorders, Hôpital de la Timone, AP-HM, Institut des Neurosciences de la Timone, Université Aix-Marseille, 13385 Marseille, France. 15. Inserm UMRS-1127, 75013 Paris, France. 16. Sorbonne Universités, UPMC Université Paris 06, Inserm UMRS-1127, CIC-1422, CNRS UMR-7225, AP-HP, ICM, Hôpital Pitié-Salpêtrière, Département des Maladies du Système Nerveux, 75013 Paris, France. 17. CHU de Clermont-Ferrand, Movement Disorders Centre, 63000 Clermont-Ferrand, France. 18. Clinical Investigation Center (CIC) 1436, Department of Clinical Pharmacolgy and Neurosciences, Inserm, Toulouse University Hospital, University of Toulouse, 31059 Toulouse, France.
Abstract
INTRODUCTION: One of the objectives of the French expert centers for Parkinson's disease (NS-Park) network was to determine a consensus procedure for assessing cognitive function in patients with Parkinson's. This article presents this procedure and briefly describes the selected tests. METHODS: A group of 13 experts used the Delphi method for consensus building to define the overall structure and components of the assessment procedure. For inclusion in the battery, tests had to be validated in the French language, require little motor participation, have normative data and be recognized by the international community. Experimental tasks and tests requiring specific devices were excluded. RESULTS: Two possibilities were identified, depending on whether an abbreviated or comprehensive assessment of cognitive function was necessary. For an abbreviated assessment, the experts recommended the Montreal Cognitive Assessment (MoCA) as a screening test for cognitive impairment or dementia. For a comprehensive neuropsychological assessment, the experts recommended assessing global efficiency plus the five main cognitive domains (attention and working memory, executive function, episodic memory, visuospatial function and language) that may be impaired in Parkinson's disease, using two tests for each domain. DISCUSSION AND CONCLUSION: A common procedure for assessing cognitive function is now available across the French network dedicated to Parkinson's disease, and is recommended for both research and clinical practice. It will also help to promote standardization of the neuropsychological assessment of Parkinson's disease.
INTRODUCTION: One of the objectives of the French expert centers for Parkinson's disease (NS-Park) network was to determine a consensus procedure for assessing cognitive function in patients with Parkinson's. This article presents this procedure and briefly describes the selected tests. METHODS: A group of 13 experts used the Delphi method for consensus building to define the overall structure and components of the assessment procedure. For inclusion in the battery, tests had to be validated in the French language, require little motor participation, have normative data and be recognized by the international community. Experimental tasks and tests requiring specific devices were excluded. RESULTS: Two possibilities were identified, depending on whether an abbreviated or comprehensive assessment of cognitive function was necessary. For an abbreviated assessment, the experts recommended the Montreal Cognitive Assessment (MoCA) as a screening test for cognitive impairment or dementia. For a comprehensive neuropsychological assessment, the experts recommended assessing global efficiency plus the five main cognitive domains (attention and working memory, executive function, episodic memory, visuospatial function and language) that may be impaired in Parkinson's disease, using two tests for each domain. DISCUSSION AND CONCLUSION: A common procedure for assessing cognitive function is now available across the French network dedicated to Parkinson's disease, and is recommended for both research and clinical practice. It will also help to promote standardization of the neuropsychological assessment of Parkinson's disease.